Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.

Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?

CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has been named the “2022 David J. Gury Company of the Year” by BioFlorida. The award recognizes one company that accomplishes significant milestones and achievements leading to the advancement of life sciences in Florida.

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

Catalyst Pharmaceuticals approaches a buy point with earnings due. Stellar ratings support the price action.

Biotech Stock Catalyst Pharmaceuticals Offers Buy Point Ahead Of Earnings

Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

Corcept Therapeutics

Vertex Pharmaceuticals

Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.

These 3 Stocks Are Winning the Bear Market -- Here's How

Aerie Pharmaceuticals

Fusion Pharmaceuticals

Jazz Pharmaceuticals

Larimar Therapeutics Inc

Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.

5 Stocks to Bet on in an Innovation-Driven Drug Industry

Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.

Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

Cardinal Health

DoubleVerify Holdings

Cheniere Energy

Neurocrine Biosciences

Paylocity Hlds

Shockwave Medical

Wolfspeed

As the market indexes work through a downturn, Vertex is among eight stocks to watch showing relative strength. The post Vertex Among 8 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.

Vertex Among 8 Stocks To Watch In Struggling Market

Here is how Catalyst Pharmaceutical (CPRX) and IMARA Inc. (IMRA) have performed compared to their sector so far this year.

Is Catalyst Pharmaceuticals (CPRX) Stock Outpacing Its Medical Peers This Year?

Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.

Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA

FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S.

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

COMPASS Pathways

Their low price tags belie their massive long-term potential.

2 No-Brainer Stocks to Buy Right Now for Less Than $15

Belite Bio Inc

Chemocentryx

Verona Pharma

Akero Therapeutics Inc

Gossamer Bio Inc

Relmada Therapeutics Inc

Viridian Therapeutics

Ventyx Biosciences

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

Looking for a Growth Stock? 3 Reasons Why Catalyst (CPRX) is a Solid Choice

Catalyst (CPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Catalyst (CPRX) Upgraded to Buy: Here's What You Should Know

BioMarin Pharmaceutical

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

Here is how Catalyst Pharmaceutical (CPRX) and Lyell Immunopharma (LYEL) have performed compared to their sector so far this year.

Is Catalyst Pharmaceuticals (CPRX) Outperforming Other Medical Stocks This Year?

Catalyst Pharmaceuticals reached a 52-week high on September 13, 2022. Catalyst was recently added to the S&P SmallCap 600 Index.

Catalyst Pharmaceuticals Ramp May Be Over For Now

Albemarle

Some companies can stand up to tough conditions on Wall Street.

As Markets Plunged, These 2 Stocks Hit All-Time Highs

Teekay Tankers

Both are in buy zones after topping follow-on patterns. The post Biotech, Tanker Stocks Hit New Highs, Top Bullish Patterns appeared first on Investor's Business Daily.

Biotech, Tanker Stocks Hit New Highs, Top Bullish Patterns

This supercharged growth stock posted a new all-time high this week.

Why Catalyst Pharmaceuticals Stock Marched Higher This Week

AVEO Pharma

Tsakos Energy Navigation Limited

Tsakos Energy Navigation (TNP), AVEO Pharmaceuticals (AVEO) and Catalyst Pharmaceuticals (CPRX) have been selected as the breakout stocks for today.

Buy These 3 Top Breakout Stocks Now for Superb Returns

CORAL GABLES, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate in the hybrid in-person and virtual H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022.

News for Catalyst Pharmaceuticals Stock (CPRX)